Filing Details
- Accession Number:
- 0001022079-22-000170
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-12-05 16:40:43
- Reporting Period:
- 2022-12-01
- Accepted Time:
- 2022-12-05 16:40:43
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1022079 | Quest Diagnostics Inc | DGX | Services-Medical Laboratories (8071) | 161387862 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1204666 | M Timothy Ring | 500 Plaza Drive Secaucus NJ 07094 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-12-01 | 972 | $62.01 | 25,121 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2022-12-01 | 1,053 | $53.13 | 26,174 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-12-01 | 2,025 | $152.50 | 24,149 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (Right to Buy) | Disposition | 2022-12-01 | 972 | $62.01 | 972 | $62.01 |
| Common Stock | Stock Options (Right to Buy) | Disposition | 2022-12-01 | 1,053 | $53.13 | 1,053 | $53.13 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2013-10-01 | 2023-10-01 | No | 4 | M | Direct |
| 0 | 2014-01-02 | 2024-01-02 | No | 4 | M | Direct |
Footnotes
- The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on June 1, 2022.
Billionaire Hedge Funds
